Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Monocytes | 9 | 2024 | 277 | 2.210 |
Why?
|
| HIV Infections | 21 | 2024 | 2586 | 1.770 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2024 | 279 | 1.670 |
Why?
|
| Cross Infection | 2 | 2025 | 48 | 1.070 |
Why?
|
| Candidiasis | 2 | 2025 | 89 | 1.050 |
Why?
|
| Disease Outbreaks | 2 | 2025 | 175 | 1.000 |
Why?
|
| AIDS Dementia Complex | 2 | 2024 | 116 | 0.940 |
Why?
|
| Corynebacterium Infections | 1 | 2025 | 1 | 0.940 |
Why?
|
| Corynebacterium | 1 | 2025 | 2 | 0.940 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2024 | 184 | 0.920 |
Why?
|
| HIV-1 | 7 | 2024 | 755 | 0.880 |
Why?
|
| Insulin Resistance | 3 | 2020 | 201 | 0.810 |
Why?
|
| Anti-HIV Agents | 7 | 2021 | 486 | 0.790 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2024 | 863 | 0.660 |
Why?
|
| Phylogeny | 1 | 2024 | 769 | 0.650 |
Why?
|
| Lipoproteins, LDL | 1 | 2020 | 67 | 0.650 |
Why?
|
| Anti-Retroviral Agents | 3 | 2019 | 160 | 0.610 |
Why?
|
| Myeloid Cells | 1 | 2019 | 31 | 0.590 |
Why?
|
| Albuminuria | 2 | 2016 | 78 | 0.570 |
Why?
|
| Brain | 1 | 2024 | 1472 | 0.480 |
Why?
|
| Receptors, Immunologic | 3 | 2024 | 73 | 0.470 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 97 | 0.460 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2020 | 247 | 0.430 |
Why?
|
| Middle Aged | 19 | 2025 | 12222 | 0.380 |
Why?
|
| Inflammation | 5 | 2025 | 758 | 0.370 |
Why?
|
| Atrophy | 2 | 2024 | 51 | 0.330 |
Why?
|
| Humans | 26 | 2025 | 43102 | 0.330 |
Why?
|
| Lymphocyte Activation | 5 | 2024 | 249 | 0.330 |
Why?
|
| Carotid Artery Diseases | 2 | 2020 | 26 | 0.280 |
Why?
|
| Male | 19 | 2025 | 23409 | 0.280 |
Why?
|
| Female | 19 | 2025 | 24698 | 0.270 |
Why?
|
| Coronary Vessels | 2 | 2019 | 92 | 0.260 |
Why?
|
| Renin-Angiotensin System | 1 | 2025 | 48 | 0.230 |
Why?
|
| Neuropsychological Tests | 2 | 2024 | 284 | 0.230 |
Why?
|
| Infection Control | 1 | 2025 | 18 | 0.230 |
Why?
|
| Genome, Fungal | 1 | 2024 | 28 | 0.220 |
Why?
|
| Molecular Epidemiology | 1 | 2024 | 59 | 0.220 |
Why?
|
| Hospitals | 1 | 2024 | 117 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2024 | 587 | 0.190 |
Why?
|
| Virus Latency | 2 | 2019 | 49 | 0.180 |
Why?
|
| Cross-Sectional Studies | 7 | 2020 | 3156 | 0.180 |
Why?
|
| Genotype | 1 | 2024 | 800 | 0.180 |
Why?
|
| Receptors, CCR2 | 2 | 2018 | 28 | 0.180 |
Why?
|
| Receptors, CCR5 | 2 | 2018 | 64 | 0.180 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2020 | 384 | 0.170 |
Why?
|
| Carotid Stenosis | 1 | 2020 | 16 | 0.160 |
Why?
|
| Fasting | 1 | 2020 | 56 | 0.160 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 37 | 0.160 |
Why?
|
| Interleukin-8 | 1 | 2020 | 74 | 0.160 |
Why?
|
| Interleukin-1beta | 1 | 2020 | 75 | 0.160 |
Why?
|
| Blood Platelets | 1 | 2020 | 81 | 0.160 |
Why?
|
| Viral Load | 2 | 2018 | 348 | 0.160 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 60 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2021 | 117 | 0.160 |
Why?
|
| Interleukin-6 | 1 | 2020 | 165 | 0.150 |
Why?
|
| Erythrocyte Indices | 1 | 2018 | 14 | 0.150 |
Why?
|
| Galectins | 1 | 2019 | 30 | 0.150 |
Why?
|
| Genetic Markers | 1 | 2019 | 150 | 0.150 |
Why?
|
| Cytokines | 2 | 2020 | 678 | 0.150 |
Why?
|
| E-Selectin | 1 | 2018 | 23 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 69 | 0.140 |
Why?
|
| Blood Glucose | 1 | 2020 | 389 | 0.140 |
Why?
|
| Erythrocytes | 1 | 2018 | 126 | 0.140 |
Why?
|
| Imidazoles | 1 | 2018 | 142 | 0.130 |
Why?
|
| Adult | 6 | 2025 | 13872 | 0.130 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2017 | 23 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 259 | 0.130 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 196 | 0.130 |
Why?
|
| Receptors, IgG | 1 | 2016 | 53 | 0.120 |
Why?
|
| Mitochondria | 1 | 2020 | 523 | 0.120 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 36 | 0.120 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 386 | 0.120 |
Why?
|
| Chronic Disease | 2 | 2016 | 549 | 0.120 |
Why?
|
| Serum Amyloid P-Component | 1 | 2015 | 21 | 0.120 |
Why?
|
| Brachial Artery | 1 | 2015 | 27 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2019 | 403 | 0.120 |
Why?
|
| Vasodilation | 1 | 2015 | 64 | 0.120 |
Why?
|
| Fibrosis | 1 | 2016 | 169 | 0.110 |
Why?
|
| Acute-Phase Proteins | 1 | 2014 | 15 | 0.110 |
Why?
|
| Chemokine CCL2 | 1 | 2016 | 95 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2025 | 2544 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 191 | 0.110 |
Why?
|
| Cognition | 1 | 2018 | 473 | 0.110 |
Why?
|
| Calcium | 1 | 2016 | 491 | 0.100 |
Why?
|
| Aged | 3 | 2025 | 8214 | 0.100 |
Why?
|
| Hippocampus | 1 | 2016 | 594 | 0.090 |
Why?
|
| RNA, Viral | 3 | 2020 | 321 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2018 | 229 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2025 | 760 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 749 | 0.070 |
Why?
|
| Hawaii | 3 | 2020 | 2011 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 2 | 2018 | 83 | 0.060 |
Why?
|
| Angiotensin I | 1 | 2025 | 9 | 0.060 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2025 | 30 | 0.060 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2025 | 41 | 0.060 |
Why?
|
| Heart Transplantation | 1 | 2025 | 47 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2025 | 317 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2025 | 72 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2025 | 76 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2025 | 93 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2025 | 257 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2025 | 307 | 0.050 |
Why?
|
| Disease Progression | 2 | 2016 | 667 | 0.050 |
Why?
|
| Phenotype | 2 | 2016 | 780 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 1063 | 0.050 |
Why?
|
| Autoantigens | 1 | 2021 | 87 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2020 | 29 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 259 | 0.040 |
Why?
|
| Uganda | 1 | 2019 | 22 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 3994 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 109 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2019 | 87 | 0.040 |
Why?
|
| Virus Activation | 1 | 2019 | 38 | 0.040 |
Why?
|
| Sulfoxides | 1 | 2018 | 18 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 69 | 0.040 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 209 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2019 | 113 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 149 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2018 | 61 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 127 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 2019 | 163 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 719 | 0.030 |
Why?
|
| Aorta | 1 | 2018 | 198 | 0.030 |
Why?
|
| Virus Replication | 1 | 2019 | 318 | 0.030 |
Why?
|
| Atherosclerosis | 1 | 2018 | 169 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2016 | 57 | 0.030 |
Why?
|
| Logistic Models | 1 | 2019 | 1009 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 592 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1285 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 201 | 0.030 |
Why?
|
| Cell Separation | 1 | 2016 | 94 | 0.030 |
Why?
|
| Calcinosis | 1 | 2016 | 62 | 0.030 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2016 | 57 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2016 | 139 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2018 | 329 | 0.030 |
Why?
|
| Cell Line | 1 | 2019 | 1410 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 1600 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 245 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2016 | 411 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2018 | 1621 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2016 | 311 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 356 | 0.030 |
Why?
|
| Comorbidity | 1 | 2016 | 737 | 0.020 |
Why?
|
| Prognosis | 1 | 2016 | 861 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 532 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 2676 | 0.020 |
Why?
|
| Aging | 1 | 2016 | 783 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2016 | 1003 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 2157 | 0.020 |
Why?
|
| Animals | 1 | 2016 | 16992 | 0.010 |
Why?
|